WorldCat Identities

Anota, Amélie

Overview
Works: 23 works in 27 publications in 2 languages and 41 library holdings
Roles: Other, Thesis advisor, Opponent, Author, Contributor
Publication Timeline
.
Most widely held works by Amélie Anota
Development and validation of the FRAGIRE tool for assessment an older person's risk for frailty by Dewi Vernerey( )

1 edition published in 2016 in English and held by 2 WorldCat member libraries worldwide

Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence by Charlotte Pourcelot( )

1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide

Impact des critères de jugement sur l'optimisation de la détermination du nombre de sujet nécessaires pour qualifier un bénéfice clinique dans des essais cliniques en cancérologie by Alhousseiny Pam( Book )

2 editions published in 2017 in French and held by 2 WorldCat member libraries worldwide

In oncology clinical trial, overall survival (OS) benefit is the gold standard for the approval of new anticancer by the regulatory agencies as the FDA. The need to reduce long-term follow-up, sample size and cost of clinical trials led to use some intermediate endpoint for OS to assess earlier efficacy of treatments. The intermediate endpoints are often used as primary endpoints because they can be assessed earlier and most of the time, these endpoints are composite endpoints because they combine different events. Nevertheless, composite endpoints suffer from important limitations specially the variability of their definitions, which is recognized as a major methodological problem. In this context, the DATECAN-1 project has been developed to provide recommendations and to standardize definitions of time-to-event composite endpoints for each specific diseases and at each specific stage by use of a formal consensus methodology. To validate surrogate endpoints, Buyse and colleagues developed a method based on individual-data meta-analysis, which assesses “individual-level” surrogacy and “trial-level” surrogacy, which is considered as the gold standard.Phase III cancer clinical trials investigators employ more and more two co-primary endpoints. However, an important challenge, in the conception of clinical trials is the sample size calculation according to the main objective(s) and the ability to manage multiple co-primary endpoints. The determination of sample size is fundamental and critical elements in the design of phase III clinical trial. If the sample size is too small, important effects may be go unnoticed. If it is too large, it represents a waste of resources and unethically puts more participants at risk than necessary. The statistical power depends on the total number of events rather than on total sample size.The objectives of my thesis project are:1) To study the impact of the definitions of time-to-event endpoint from the DATECAN-1 consensus on the results and conclusions of the trials published in pancreatic cancer.2) To study the properties of the potential surrogate to the overall survival.3) To propose a design for the determination of sample size necessary for a phase III clinical study with co-primary time-to-event such as progression-free survival and time to quality of life deterioration.The final objective of my thesis project is to develop an R package for the calculation of the number of subjects needed with the co-primary time-to-event in phase III clinical trials
The relationship between traits optimism and anxiety and health-related quality of life in patients hospitalized for chronic diseases: data from the SATISQOL study by Sabrina Kepka( )

1 edition published in 2013 in English and held by 2 WorldCat member libraries worldwide

Analyse longitudinale des données de qualité de vie relative à la santé en cancérologie : vers une standardisation de la méthode du temps jusqu'à détérioration by Emilie Charton( )

2 editions published in 2020 in French and held by 2 WorldCat member libraries worldwide

The purpose/aim of this thesis is to contribute to the analysis and comparison of PROs (« patient-reported outcomes ») data in oncology clinical trials. The interpretation of such results remains complex and unstandardized. One of the many ways to carry out a longitudinal analysis of PRO data is the time to deterioration (TTD) approach. Within of the scope of this project, some of the research examined which definitions of TTD are used and pointed out that some recommendations have not been followed. Moreover, due to the variability of the definitions in use, the comparison of various results from clinical trials is compromised. A clear definition of what is considered to be a « deterioration » is required for the TTD approach. It will depend on many criteria such as the location of the cancer, the therapeutic setting, the reference score, the minimal important difference perceived by the patient, as well as on censoring rules. Two SAS macros were developed on the TTD method as a way to optimize and harmonize the TTD definitions that are being used, as well as to be able to have comparable results and consequently a way to help standardize those definitions. In this perspective, a study conducted on a cohort of adjuvant breast cancer patients led to more focus on the first deterioration of the patient and the management of non-randomization at baseline. In parallel, this method was also implemented for a randomized phase II trial on patients with metastatic pancreatic cancer. During this trial, the impact of the occurrence of missing data at baseline was handled by applying a multiple imputation based on the Markov Chain Monte Carlo method. These works highlight the need to continue developing a consensus for the longitudinal analysis of PROs data in oncology clinical trials
Methodology of health-related quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: a critical review by Frédéric Fiteni( )

1 edition published in 2016 in English and held by 2 WorldCat member libraries worldwide

Modeling strategies to improve parameter estimates in prognostic factors analyses with patient-reported outcomes in oncology by Francesco Cottone( )

1 edition published in 2019 in English and held by 2 WorldCat member libraries worldwide

Item response theory and factor analysis as a mean to characterize occurrence of response shift in a longitudinal quality of life study in breast cancer patients by Amélie Anota( )

1 edition published in 2014 in English and held by 2 WorldCat member libraries worldwide

Health related quality of life in breast cancer patients : a systematic review in the middle eastern population, application of lebanese prospective study and an analysis of time to deterioration of utility values of french database by Rana El Haidari( )

2 editions published in 2021 in English and held by 2 WorldCat member libraries worldwide

The main purpose of the present thesis was to identify the different factors associated to the Health related quality oflife (HRQoL) among breast cancer (BC) women in the Middle-East (ME) and to explore the direction of change of body image after breast conserving surgery among women who live in Lebanon; while also attempting to apply the time to deterioration in utility value, as an approach oflongitudinal analysis. The first study identified several modifiable and non-modifiable factors that affect HRQoL in women with BC in the ME. This is a public health significance and provides a framework for establishing policy interventions to prevent factors influencing negatively on the HRQoL. Similarly, healthcare systems in the ME are encouraged to develop targeted interventional programs on modifiable factors, particularly socio-demographic, behavioral and psychosocial ones. Further, research on these factors is warranted, preferably through prospective longitudinal studies. The second study has also contributed to knowledge that early BC women's HRQoL change significantly after surgery in some domains (physical fonction, emotional fonction and body image). Nevertheless, some risk factors for poor HRQoL were identified, including decreased body image and decreased future perspective. These findings highlight the importance of considering multidimensional interventions such as psychological consultation, social support and offering education about therapeutic follow-up. Moreover, future prospective studies with a larger cohort and longer follow-up are needed to confirm our findings and design interventional trials to improve HRQoL in BC patients. The third study highlights that in order to improve the HRQoL of the patients with BC, it is important to estimate the psychological burden caused by the treatment and the need to find measures to reduce it. Therefore, BC patients undergoing therapy need psychological support to cope with their discomfort, pain, depression, anxiety and fear during the process of diagnosis and treatment in order to improve their QoL
A longitudinal analysis of patient satisfaction with care and quality of life in ambulatory oncology based on the OUT-PATSAT35 questionnaire by Thanh Vân France Nguyen( )

1 edition published in 2014 in English and held by 2 WorldCat member libraries worldwide

Impact of the occurrence of a response shift on the determination of the minimal important difference in a health-related quality of life score over time by Ahmad Ousmen( )

1 edition published in 2016 in English and held by 2 WorldCat member libraries worldwide

Erratum to: Development and validation of the FRAGIRE tool for assessment an older person's risk for frailty by Dewi Vernerey( )

1 edition published in 2016 in English and held by 2 WorldCat member libraries worldwide

Distribution- and anchor-based methods to determine the minimally important difference on patient-reported outcome questionnaires in oncology: a structured review by Ahmad Ousmen( )

1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide

Health-related quality of life as an endpoint in oncology phase I trials: a systematic review by Frédéric Fiteni( )

1 edition published in 2019 in English and held by 2 WorldCat member libraries worldwide

Détermination du sens clinique d'un changement pour les questionnaires de qualité de vie relative à la santé en cancérologie by Ahmad Ousmen( )

1 edition published in 2019 in French and held by 1 WorldCat member library worldwide

In oncology, the health-related quality of life (HRQOL) is generally considered as a second endpoint in the clinical trials. The interpretation of the results of the longitudinal analysis of such data must be made in both statistical and clinical point of view in order to produce meaningful results for both patients and clinicians. The main objective is to assess the impact of the treatment on patient's HRQOL level over time. The minimal clinically important difference (MCID) was defined as the smallest change between two scores in a treatment outcome that a patient would identify as important. Indeed, the longitudinal analysis of HRQOL remains complex, particularly due to the potential occurrence of a Response Shift effect characterizing the process of adaptation of the patient in relation to the illness and its treatment. Hence, the first objective of this work is a literature review concerning the determination of the MCID by the most commonly used methods: anchor-based and distribution-based methods. Secondly, calculating the MCID using anchor-based and distribution-based methods by applying different distribution criteria and several different anchors. The objective is to compare the results obtained by the different methods and to compare them to others obtained by previous studies. Finally, studying the impact of the Response Shift effect on the determination of MCID for the HRQOL questionnaires in cancer research using several data corresponding to different therapeutic situations and cancer locations
Longitudinal health-related quality of life analysis in oncology with time to event approaches, the STATA command qlqc30_TTD( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Highlights: The first Stata command dedicated to the longitudinal analysis of HRQoL which allows performing the TTD and TUDD approaches. A Stata command providing an automatic analysis and results in tabular forms as well as Kaplan-Meier plots. A Stata command providing a reliable analysis, indeed, a cross validation was performed which ensures a high verification and validation of the scripts. A longitudinal analysis of the HRQOL data of the CO-HO-RT randomized trial is proposed. This Stata command will be of great help and will allow a more systematic and quicker analysis of the HRQoL data in clinical trials in oncology. Abstract: Background and objective: Health-related quality of life (HRQoL) has become one relevant and available alternative endpoint of clinical trials in cancer research to evaluate efficiency of care both for the patient and health system. HRQoL in oncology is mainly assessed using the 30-item European Organisation for Research and Treatment of Cancer Quality of Life--Questionnaire Core 30 (EORTC QLQ-C30). The EORTC QLQ-C30 questionnaire is usually assessed at different times along the clinical trials in order to analyze the kinetics of HRQoL evolution and to fully assess the impact of the treatment on the patient's HRQoL level. In this perspective, the realization of a longitudinal HRQoL analysis is essential and the time to HRQoL score deterioration approach is a method which is more and more used in clinical trials. Method: Using the Stata software, we developed a QLQ-C30 specific command, qlqc30_TTD, which implements longitudinal strategies based on the time to event methods by considering the time to HRQoL score deterioration. This user-written command providing automatic execution of the Time To Deterioration (TTD) and Time Until Definitive Deterioration (TUDD) methods. Result: The program implements all published definitions and provides the Kaplan-Meier curves for each dimension (by group) and a table with the Hazard Ratio and Log-Rank test. Conclusion: The longitudinal analysis of HRQoL data in cancer clinical trials remains complex with only few programs like ours computed. This program will be of great help and will allow a more systematic and quicker analysis of the HRQoL data in clinical trials in oncology
 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  General Special  
Audience level: 0.00 (from 0.00 for Developmen ... to 0.00 for Developmen ...)

Languages
English (18)

French (5)